When was Diffuse Bio founded?

Diffuse Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Diffuse Bio located?

Diffuse Bio is headquartered in San Francisco, United States.

Is Diffuse Bio a funded company?

Diffuse Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2023.

When was the latest funding round of Diffuse Bio?

Diffuse Bio's latest funding was a $***** Seed round on 2023, with participation from 1 investor. Its primary sector is Generative AI. In United States, the Generative AI sector has seen $253B in funding in 2026 to date.

Where does Diffuse Bio rank among its competitors?

Diffuse Bio ranks 25th amongst 135 active competitors, of which 42 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Unnatural Products, which secured $45M in Mar, 2026.

Who are the top competitors of Diffuse Bio?

Diffuse Bio's top competitors include Seer, Biognosys and Peptris. Among them, Unnatural Products secured the most recent funding round in March, 2026.

Diffuse Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of AI-based drug candidate identification solutions for drug discovery. It is offering AI-software platform for drug design and experimental validation of AI-generated proteins and diffusion models for protein structure and sequences.

Website: www.diffuse.bio/
Email ID: *****@diffuse.bio

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, 2023, $*****

Investors

GreatPoint Ventures & 1 more

Ranked

25^th among 135 active competitors

Similar Companies

OpenEvidence & 2497 more

View Diffuse Bio's full profile

Diffuse Bio has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on 2023 for $*****. 1 investor participated in its latest round. Diffuse Bio has 2 institutional investors.

Here is the list of recent funding rounds of Diffuse Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2023	1702	Seed	2358	8438	4028	2575

Access funding benchmarks and valuations. Sign up today!

View details of Diffuse Bio's funding rounds and investors

The founders of Diffuse Bio is Namrata Anand.

Here are the details of Diffuse Bio's key team members:

Namrata Anand: Founder of Diffuse Bio.
Contact Info: 1 email address

View details of Diffuse Bio's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Diffuse Bio include Seer, Biognosys and Peptris. Here is the list of Top 10 competitors of Diffuse Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Redalpine & 6 others	63/100
3rd	Peptris 2019, Bengaluru (India), Series A	Provider of AI-based proteomic data analysis software for drug discovery	$9.17M	Speciale Invest, Indian Angel Network Fund ... & 46 others	60/100
4th	Peptone 2016, Amsterdam (Netherlands), Series A	Provider of an AI based protein analysis platform for research and development	$42.5M	Bessemer Venture Partners, F-Prime Capital ... & 6 others	60/100
5th	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Two Bear Capital & 11 others	60/100
6th	Unnatural Products 2016, Santa Cruz (United States), Series B	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$83M	Merck Global Health Innovation Fund, Artis Ventures ... & 17 others	58/100
7th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	Lapam Capital, Deyi Capital & 8 others	57/100
8th	Atavistik 2021, Cambridge (United States), Series B	Developer of allosteric therapeutics for precision oncology and rare diseases	$260M	The Column Group, Nextech Invest & 3 others	55/100
9th	Avenue Biosciences 2023, Palo Alto (United States), Seed	Biotechnology company that employs protein engineering solutions	$15.6M	Voima Ventures, Balnord & 4 others	54/100
10th	Grove Biopharma 2020, Chicago (United States), Series A	Developer of AI-based drug modality platform for protein-based drugs	$34M	DCVC, Skydeck Capital & 10 others	54/100
25th	Diffuse Bio 2022, San Francisco (United States), Seed	Provider of AI-based drug candidate identification solutions for drug discovery	$500K	GreatPoint Ventures, Y Combinator	41/100